• Users Online: 427
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2021  |  Volume : 7  |  Issue : 1  |  Page : 7-11

Crisaborole for the treatment of atopic dermatitis in Indian patients: An evidence-based consensus statement

1 Department of Dermatology, Dr. DY Patil Medical College, Nerul, Navi Mumbai, Maharashtra, India
2 Department of Dermatology, Calcutta National Medical College, Kolkata, West Bengal, India
3 Department of Dermatology, The Medicity, Medanta Hospital, Gurugram, Haryana, India
4 Department of Dermatology, Apollo Hospital, Chennai, Tamil Nadu, India
5 Department of Dermatology, BJ Medical College, Ahmedabad, Gujarat, India
6 Department of Dermatology, Max Super Speciality Hospital, New Delhi, India
7 Department of Dermatology, Skin Diseases Center, Nashik, Maharashtra, India
8 Department of Dermatology, Krupa Shankar Skin Care Center, Mallige Hospital, Bengaluru, Karnataka, India
9 Department of Dermatology, MGM Medical College, Nerul, Navi Mumbai, India
10 Department of Pharmacology, Dr. DY Patil Medical College, Nerul, Navi Mumbai, India

Correspondence Address:
Kiran Godse
Department of Dermatology, Dr. DY Patil Medical College, Nerul, Navi Mumbai, Maharashtra
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/ijdd.ijdd_35_20

Rights and Permissions

Atopic dermatitis is a chronic inflammatory dermatological condition associated with intense pruritus seen in all age groups and ethnic diversities. It can have a significant impact on the quality of life. The options for treatment include skincare, topical therapies, systemic therapies, and phototherapy. Treatment of atopic dermatitis may be associated with several challenges including suboptimal efficacy, risk of adverse events, and limited patient satisfaction. A better understanding of the pathophysiology of atopic dermatitis has resulted in the evaluation of many treatment options. Phosphodiesterase 4 plays a role in the pathogenesis of atopic dermatitis and hence can be a target for treatment. Crisaborole 2% ointment is a phosphodiesterase 4 enzyme inhibitor approved for the treatment of mild-to-moderate atopic dermatitis in patients above 2 years of age by the USFDA. Currently, it is not approved for use in Indian patients. In this article, the role and potential place of crisaborole in the management of atopic dermatitis in Indian patients based on global experience and evidence is discussed.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded141    
    Comments [Add]    

Recommend this journal